期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Glucagon-like peptide-1 agonists:Role of the gut in hypoglycemia unawareness,and the rationale in type 1 diabetes
1
作者 Hyder O Mirghani 《World Journal of Diabetes》 SCIE 2024年第11期2167-2172,共6页
Type 1 diabetes is increasing and the majority of patients have poor glycemic control.Although advanced technology and nanoparticle use have greatly enhanced insulin delivery and glucose monitoring,weight gain and hyp... Type 1 diabetes is increasing and the majority of patients have poor glycemic control.Although advanced technology and nanoparticle use have greatly enhanced insulin delivery and glucose monitoring,weight gain and hypoglycemia remain major challenges and a constant source of concern for patients with type 1 diabetes.Type 1 diabetes shares some pathophysiology with type 2 diabetes,and an overlap has been reported.The above observation created great interest in glucagon-like peptide-1 receptor agonists(GLP-1)as adjuvants for type 1 diabetes.Previous trials confirmed the positive influence of GLP-1 agonists onβcell function.However,hypoglycemia unawareness and dysregulated glucagon response have been previously reported in patients with recurrent hypoglycemia using GLP-1 agonists.Jin et al found that the source of glucagon dysregulation due to GLP-1 agonists resides in the gut.Plausible explanations could be gut nervous system dysregulation or gut microbiota disruption.This review evaluates the potential of GLP-1 agonists in managing type 1 diabetes,particularly focusing on their impact on glycemic control,weight management,and glucagon dysregulation.We provide a broader insight into the problem of type 1 diabetes mellitus management in the light of recent findings and provide future research directions. 展开更多
关键词 glucagon-like peptide-1 receptor agonists glucagon response Hypoglycemia unawareness GUT Type 1 diabetes
下载PDF
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease:Opportunities and challenges
2
作者 Chencheng Xie Naim Alkhouri Mohamed A Elfeki 《World Journal of Hepatology》 2024年第5期731-750,共20页
Metabolic dysfunction-associated steatotic liver disease(MASLD)has become the most common chronic liver disease worldwide,paralleling the rising pandemic of obesity and type 2 diabetes.Due to the growing global health... Metabolic dysfunction-associated steatotic liver disease(MASLD)has become the most common chronic liver disease worldwide,paralleling the rising pandemic of obesity and type 2 diabetes.Due to the growing global health burden and com-plex pathogenesis of MASLD,a multifaceted and innovative therapeutic approach is needed.Incretin receptor agonists,which were initially developed for diabetes management,have emerged as promising candidates for MASLD treatment.This review describes the pathophysiological mechanisms and action sites of three major classes of incretin/glucagon receptor agonists:glucagon-like peptide-1 receptor agonists,glucose-dependent insulinotropic polypeptide receptor agonists,and glucagon receptor agonists.Incretins and glucagon directly or indirectly impact various organs,including the liver,brain,pancreas,gastro-intestinal tract,and adipose tissue.Thus,these agents significantly improve glycemic control and weight management and mitigate MASLD pathogenesis.Importantly,this study provides a summary of clinical trials analyzing the effect-iveness and safety of incretin receptor agonists in MASLD management and provides an in-depth analysis highlighting their beneficial effects on improving liver function,hepatic steatosis,and intrahepatic inflammation.There are emerging challenges associated with the use of these medications in the real world,particularly adverse events,drug-drug interactions,and barriers to access,which are discussed in detail.Additionally,this review highlights the evolving role of incretin receptor agonists in MASLD management and suggests future research directions. 展开更多
关键词 Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis glucagon-like peptide-1 Glucose-dependent inulinotropic polypeptide glucagon INCRETIN receptor agonist
下载PDF
新型糖尿病治疗药物:德谷胰岛素利拉鲁肽注射液 被引量:6
3
作者 母义明 胡蓓 《临床药物治疗杂志》 2022年第6期16-20,共5页
德谷胰岛素利拉鲁肽注射液是全球首个基础胰岛素胰高糖素样肽-1受体激动剂注射液,也是糖尿病治疗领域首个新型生物制剂联合药物。其在分子基础上实现双受体激活;在作用机制上实现“协同互补,靶向调节”、在临床治疗上实现“增效减副,综... 德谷胰岛素利拉鲁肽注射液是全球首个基础胰岛素胰高糖素样肽-1受体激动剂注射液,也是糖尿病治疗领域首个新型生物制剂联合药物。其在分子基础上实现双受体激活;在作用机制上实现“协同互补,靶向调节”、在临床治疗上实现“增效减副,综合获益”。本文对德谷胰岛素利拉鲁肽注射液的创新点及其临床数据进行梳理,旨在论证其创新性和临床价值。 展开更多
关键词 德谷胰岛素利拉鲁肽注射液 糖尿病 基础胰岛素 胰高糖素样肽-1受体激动剂
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部